Skip to main content

Table 5 Adjusted effect size by duration of follow-up

From: Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: a systematic review and meta-analysis

   

Model 1

Model 2

Model 3

Model 4

Model 5

Model 6

Model 7

Model 8

 

N

%

Coefficient (95% CI)

Coefficient (95% CI)

Coefficient (95% CI)

Coefficient (95% CI)

Coefficient (95% CI)

Coefficient (95% CI)

Coefficient (95% CI)

Coefficient (95% CI)

Const

  

0.784 (0.703; 0.865)

0.624 (0.508; 0.740)

0.653 (0.562; 0.744)

0.639 (0.535; 0.742)

0.696 (0.555; 0.838)

0.612 (0.454; 0.77)

0.616 (0.463; 0.768)

 

Measures

          

SG

20

8.6

        

VAS

81

34.6

0.037 (−0.021; 0.095)

0.067 (−0.048; 0.182)

0.06 (−0.038; 0.158)

0.063 (−0.041; 0.168)

0.072 -0.038; 0.182)

0.066 (−0.059; 0.191)

0.073 (−0.060; 0.207)

0.535 (0.425; 0.645)

TTO

20

8.6

0.151 (0.098; 0.203)

0.209 (0.086; 0.331)

0.180 (0.097;0.264)

0.191 (0.096; 0.285)

0.199 (0.091; 0.307)

0.207 (0.080; 0.334)

0.213 (0.079; 0.348)

0.555 (0.377; 0.733)

15D

2

0.9

0.017 (−0.059; 0.094)

0.069 (−0.072; 0.211)

0.040 (−0.064; 0.144)

0.065 (−0.063; 0.193)

0.064 (−0.054; 0.182)

0.067 (−0.072; 0.205)

0.076 (−0.076; 0.227)

0.493 (0.335; 0.651)

SF6D

7

3

0.171 (0.11; 0.231)

0.214 (0.077; 0.350)

0.189 (0.095; 0.283)

0.199 (0.093; 0.306)

0.201 (0.095; 0.307)

0.201 (0.078; 0.325)

0.217 (0.074; 0.360)

0.613 (0.455; 0.771)

HUI

31

13.3

−0.052 (−0.127; 0.022)

−0.042 (−0.178; 0.093)

−0.055 (−0.159; 0.049)

−0.044 (−0.159; 0.072)

−0.041 (−0.153; 0.071)

−0.052 (−0.180; 0.076)

−0.04 (−0.187; 0.106)

0.319 (0.173; 0.465)

EQ5D

73

31.2

0.114 (0.048; 0.179)

0.124 (−0.006; 0.254)

0.113 (0.016; 0.210)

0.124 (0.015; 0.234)

0.125 (0.021; 0.229)

0.116 (−0.005; 0.237)

0.127 (−0.015; 0.268)

0.541 (0.407; 0.676)

Length of ART

          

Length of ART _1

         

−0.148 (−0.274; −0.021)

Length of ART _2

         

0.397 (0.034; 0.760)

Study design

          

Cross-sectional

123

52.6

        

Longitudinal

111

47.4

     

0.033 (−0.027; 0.092)

  

Disease stages

          

Asymptomatic

22

9.4

        

Symptomatic

41

17.5

−0.017 (−0.094; 0.059)

   

−0.025 (−0.084; 0.034)

   

AIDS

67

28.6

−0.173 (−0.261; −0.086)

   

−0.176 (−0.278; −0.075)

   

Mixed group

104

44.4

−0.061 (−0.120; −0.002)

   

−0.057 (−0.124; 0.009)

   

Treatment

          

Non ART

63

26.9

        

ART

150

64.1

−0.076 (−0.150; −0.002)

  

−0.067 (−0.170; 0.036)

    

Combined

21

9

−0.015 (−0.074; 0.045)

  

0.025 (−0.016; 0.066)

    

Setting

          

Developed

182

77.8

        

Developing

52

22.2

−0.082 (−0.163; −0.001)

 

−0.094 (−0.216; 0.029)

    

−0.087 (−0.187; 0.012)

Year

          

2000/4

38

16.2

        

2005/9

149

63.7

−0.023 (−0.074; 0.029)

−0.017 (−0.094; 0.059)

     

0.196 (0.067; 0.325)

2010/3

47

20.1

0.039 (−0.036; 0.115)

0.014 (−0.036; 0.064)

     

0.248 (0.064; 0.431)

  1. Figures in bold: p-values<0.05.